
The Value of Membership



We present a unified, credible, and professional voice for the sector to policy makers at all levels of government.

We connect you with psychedelic company executives across Canada and the decisionmakers who shape our regulatory operating environment.

We gather intelligence on economic and regulatory trends in the psychedelic medicine and therapy sector, with early or privileged access for members.

Our Asks of Government

- We seek a rational, non-partisan, and science-informed discussion about psychedelics, without politicization.
- We are calling for parliamentary committees to investigate and hold hearings on the benefits of psychedelic medicine and therapy.
- We are calling for a National Task Force to examine regulatory reforms to increase patient access.
- We are calling for reforms to increase the efficiency and transparency of the Special Access Program, up to and including the establishment of a standalone Psychedelic Access Program.
- We are calling for increased federal funding for clinical trials investigating psychedelic-assisted psychotherapy.



Membership Guide

Welcome to **PsyCan**, the not-for-profit trade association of legally operating Canadian psychedelic medicine and therapy companies.

We are researchers, healthcare providers, drug developers, and suppliers producing and working with psychedelic medicine.

Our sector is comprised of ~80 small and medium-sized companies worth over a billion dollars. We employ thousands of Canadians advancing the frontiers of healthcare innovation.


Together, we deliver psychedelic medicine and therapy through qualified professionals to treat patients suffering from a variety of health problems.

Our Structure

- PsyCan is a legally registered not-for-profit corporation. We operate according to our governing by-laws, resolutions and motions passed at our board and member meetings, and in accordance with all applicable federal, provincial, territorial, and municipal laws.
- We have a Board of Directors, elected by the representatives of our members, which provides overall executive leadership, elected at our Annual General Meeting, held in April.
- We have a Government Relations Working Group, where members help shape government relations strateav.
- We have staff, led by our Coordinator Liam Bedard, who executes instructions from the board and members and manages the day-to-day work of the association.

Affiliation Categories

- 1. Full Members: companies directly implicated in psychedelic medicine and therapy.
- 2. Associate Members: companies not directly implicated but who provide services to companies in the sector and who are invested in its success, and,
- 3. Community Partners: charitable and advocacy organizations dedicated to public awareness of the benefits of psychedelic medicine. Unlike the previous categories, they have voice, but no vote, in our decisionmaking processes.





Esther Simmons Foot, PsvCan Vice-Chair Dr. Philippe Lucas, PsvCan Vice-Chair President, EntheoTech Bioscience



President, SABI Mind



CEO, Psygen



Danny Motyka, PsyCan Treasurer Gabriel Fahel, PsyCan Board Member Chief Legal Officer, Cybin



Chris Bryan, PsyCan Board Member VP of Research & Operations, Algernon Pharmaceuticals

Fees and Finances

Dues can be paid on a quarterly basis (\$1,250 CAD) or **yearly basis (\$5,000).** Dues are set by the board. Yearly financial statements are prepared with the support of our registered accountant, approved at our AGM, and submitted to the Canada Revenue Agency.

Resources

Link to PsyCan's 2023 White Paper Link to PsyCan's 2023 Sector Report Link to PsyCan's 2023 Open Letter on Psychedelic Access Link to PsyCan's 2022 Pre-Budget Submission

